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Background: In 2006, the Senegalese National Malaria Control Programme recommended artemisinin-based
combination therapy (ACT) as the first-line treatment for uncomplicated malaria. Since the introduction of ACT,
there have been very few reports on the level of Plasmodium falciparum resistance to anti-malarial drugs. An ex vivo
susceptibility study was conducted on local isolates obtained from the Hôpital Principal de Dakar (Dakar, Senegal)
from November 2013 to January 2014.
Methods: Eighteen P. falciparum isolates were sussessfully assessed for ex vivo susceptibility to chloroquine (CQ),
quinine (QN), monodesethylamodiaquine (MDAQ), the active metabolite of amodiaquine, mefloquine (MQ),
lumefantrine (LMF), artesunate (AS), dihydroartemisinin (DHA), the active metabolite of artemisinin derivatives,
pyronaridine (PND), piperaquine (PPQ), and, Proveblue (PVB), a methylene blue preparation, using the HRP2-based
ELISA test.
Results: The prevalence of isolates with reduced susceptibility was 55.6% for MQ, 50% for CQ, 5.6% for QN and
MDAQ, and 0% for DHA, AS and LMF. The mean IC50 for PND, PPQ and PVB were 5.8 nM, 32.2 nM and 5.3 nM,
respectively.
Conclusions: The prevalence of isolates with a reduced susceptibility to MQ remains high and stable in Dakar.
Since 2004, the prevalence of CQ resistance decreased, but rebounded in 2013 in Dakar. PND, PPQ and PVB
showed high in vitro activity in P. falciparum parasites from Dakar.
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In response to increasing chloroquine resistance, Senegal
switched in 2004 to sulphadoxine-pyrimethamine with
amodiaquine as the first-line therapy for malaria. In 2006,
the Senegalese National Malaria Control Programme rec-
ommended artemisinin-based combination therapy (ACT)
as the first-line treatment for uncomplicated malaria. The
combined sulphadoxine-pyrimethamine and amodiaquine
treatment was changed to artemether-lumefantrine or* Correspondence: bruno.pradines@free.fr
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unless otherwise stated.artesunate-amodiaquine. Since 2006, more than 1.5 mil-
lion ACT-based treatments have been administered in
Senegal [1]. In 2006, the Senegalese National Malaria
Control Programme also recommended testing all sus-
pected cases of malaria with the Plasmodium falciparum
histidine-rich protein 2 (PfHRP2)-based rapid diagnostic
test (RDT). Since this time, ACT use has been restricted
to confirmed malaria cases to reduce drug resistance. In
2009, 184,170 doses of ACT were dispensed at public
health facilities in Senegal [2].
Since the introduction of ACT, there have been very
few reports on the level of P. falciparum resistance to
anti-malarial drugs. The last ex vivo susceptibility study
was conducted in 2010 in Dakar (Médina district) [3]
and in 2011 in Thies [4]. To determine whether parasiteis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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policies, an ex vivo susceptibility study was conducted
on local isolates from Dakar obtained from the Hôpital
Principal de Dakar between November 2013 and January
2014. The malaria isolates were assessed for susceptibil-
ity to standard drugs such as chloroquine (CQ), quinine
(QN), monodesethylamodiaquine (MDAQ), the active
metabolite of amodiaquine, mefloquine (MQ), lumefan-
trine (LMF), artesunate (AS), dihydroartemisinin (DHA),
the active metabolite of artemisinin derivatives, and new
anti-malarial drugs, such as pyronaridine (PND), pipera-
quine (PPQ) and Proveblue (PVB), a methylene blue prep-
aration that complies with the European Pharmacopoeia
and contains limited organic impurities and heavy metals
of recognised toxicity.
Methods
Plasmodium falciparum isolates
In total, 24 patients (seven females and 17 males) with
malaria were recruited from 19 November 2013 to 7
January 2014 at the Hôpital Principal de Dakar. Venous
blood samples were collected in Vacutainer® ACD tubes
(Becton Dickinson, Rutherford, NJ, USA) prior to patient
treatment. Parasitaemia ranged from 0.001 to 0.33% in
the male group and from 0.001 to 3.3% in the female
group. Of the 24 patients, 67% were recruited from the
emergency department and the remainder were re-
cruited from the intensive care unit (21%), paediatric de-
partment (8%) and maternity department (4%). Informed
verbal consent was obtained from patients and/or their
parents before blood collection. Assessments of P.
falciparum susceptibility to anti-malarial drugs were
performed with the same venous blood sample used for
diagnostic purposes. The study was reviewed and ap-
proved by the ethical committee of the Hôpital Principal
de Dakar. Patients were successfully treated by QN.
Thin blood smears were stained using a RAL® kit
(Réactifs RAL, Paris, France) based on eosin and methy-
lene blue and were examined to determine P. falciparum
density and to confirm monoinfection. Parasitized eryth-
rocytes were washed three times in RPMI 1640 medium
(Invitrogen, Paisley, UK) buffered with 25 mM HEPES
and 25 mM NaHCO3. If parasitaemia exceeded 0.5%, in-
fected erythrocytes were diluted to 0.5% with uninfected
erythrocytes (human blood type A+) and resuspended in
RPMI 1640 medium supplemented with 10% human
serum (Abcys S.A. Paris, France), for a final haematocrit
of 1.5%.
Drugs
CQ, QN and DHA were purchased from Sigma (Saint
Louis, MO, USA). MDAQ was obtained from the World
Health Organization (Geneva, Switzerland), MQ was
purchased from Roche (Paris, France), and LMF waspurchased from Novartis Pharma (Basel, Switzerland).
AS, PPQ and PND were obtained from Shin Poong
Pharm Co (Seoul, Korea) and PVB from Provepharm
SAS (Marseille, France). QN, MDAQ, MQ, DHA, AS,
and PPQ were first dissolved in methanol and then di-
luted in water to final concentrations ranging from 6
nM to 3,149 nM for QN, 1.9 to 1,988 nM for MDAQ,
1.5 to 392 nM for MQ, 0.1 to 107 nM for DHA, 0.1 to
98 nM for AS and 1.9 to 998 nM for PPQ. CQ, PND
and PVB were resuspended and diluted in water to final
concentrations ranging from 6 nM to 3,231 nM, 0.4 to
199 nM and 0.5 to 500 nM, respectively. LMF was resus-
pended and diluted in ethanol to obtain final concentra-
tions ranging from 0.6 nM to 310 nM.
The batches of plates were tested and validated on the
CQ-susceptible 3D7 strain (West-Africa) and the CQ-
resistant W2 strain (Indochina) (MR4, Virginia, USA) in
three to six independent experiments using the same
conditions described in the paragraph below. The two
strains were synchronized twice with sorbitol before use
[5], and clonality was verified every 15 days using PCR
genotyping of the polymorphic genetic markers msp1
and msp2 and microsatellite loci [6,7] and annually by
an independent laboratory from the Worldwide Anti-
malarial Resistance Network (WWARN).
Ex vivo assay
For the in vitro isotopic microtests, 100 μl of synchron-
ous parasitized red blood cells (final parasitaemia, 0.5%;
final haematocrit, 1.5%) was aliquoted into 96-well plates
pre-dosed with anti-malarial drugs. The plates were in-
cubated in a sealed bag for 72 hrs at 37°C with the at-
mospheric generators for capnophilic bacteria, Genbag
CO2® at 5% CO2 and 15% O2 (BioMérieux, Marcy
l’Etoile, France) [8]. After thawing the plates, haemolysed
cultures were homogenized by vortexing the plates. Both
the success of the drug susceptibility assay and the ap-
propriate volume of haemolysed culture to use for each
assay were determined for each clinical isolate during a
preliminary HRP2 ELISA. Both the pre-test and subse-
quent ELISAs were performed using a commercial kit
(Malaria Ag Celisa, ref KM2159, Cellabs PTY LTD,
Brookvale, Australia) according to the manufacturer’s
recommendations. The optical density (OD) of each
sample was measured with a spectrophotometer (Multis-
kan EX, Thermo Scientific, Vantaa, Finland).
The concentration at which the drugs were able to in-
hibit 50% of parasite growth (IC50) was calculated with
the inhibitory sigmoid Emax model, with estimation of
the IC50 through non-linear regression using a standard
function of the R software (ICEstimator version 1.2) [9].
IC50 values were validated only if the OD ratio (OD at
concentration 0/OD at concentration max) was greater
than 1.6 and the confidence interval ratio (upper 95%
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confidence interval of the IC50 estimation) was less than
2.0 [9].
Data and statistical analysis
IC50 values were analysed after logarithmic transform-
ation and expressed as the geometric mean of the IC50
and a confidence interval of 95% (CI95%).
Using the Genbag conditions, the cut-off values for
in vitro resistance, or reduced susceptibility, were 77
nM, 61 nM, 115 nM, 12 nM, 12 nM, 611 nM, and 30
nM for CQ, MDAQ, LMF, DHA, AS, QN, and MQ, re-
spectively [10].
Results
Of the 24 patients recruited at the Hôpital Principal de
Dakar, 19 were tested ex vivo, and 18 isolates were suc-
cessfully cultured. The average parameter estimates for
the ten anti-malarial drugs used against the P. falcip-
arum isolates are given in Table 1. The prevalence of P.
falciparum isolates with decreased susceptibility to MQ
in vitro reached 55.6%. Fifty per cent of the isolates were
resistant in vitro to CQ.
Discussion
This report describes the evaluation of the ex vivo sus-
ceptibility of P. falciparum isolates, taken from patients
in Dakar, to ten standard or potential anti-malarial
drugs. The patients, recruited at the Hôpital Principal de
Dakar from November 2013 to January 2014, said that
they did not leave Dakar and its surrounding suburbs
during the month preceding their malaria attack.
One limitation of this study was the low number of re-
cruited patients (24) during those two months, due toTable 1 Ex vivo susceptibility of 18 Plasmodium falciparum
monodesethylamodiaquine (MDAQ), lumefantrine (LMF), d
(MQ), artesunate (AS), pyronardine (PND), piperaquine (PP
Drug Isolate IC50
Mean CI 95% Min
CQ 52.2 nM 29.1-93.9 6.1
MDAQ 9.8 nM 5.5-17.4 1.9
LMF 4.1 nM 2.1-8.1 0.61
DHA 0.72 nM 0.35-1.50 0.1
AS 1.35 nM 0.53-3.42 0.12
QN 63.1 nM 30.9-128.7 6.2
MQ 30.1 nM 19.4-46.6 7.1
PND 5.8 nM 3.3-10.1 0.4
PPQ 32.2 nM 16.5-62.8 2.5
PVB 5.3 nM 2.8-10.1 0.9
Mean: geometric mean.
CI 95%: 95% confidence interval.
ND: not determined.the diminution of malaria prevalence in Senegal. The
malaria prevalence in public health facilities decreased
from 17.9% in 2007 to 2.6% in 2008 in Dakar [11]. In
Dielmo, a village located at 280 km southeast of Dakar
and approximately 15 km north of The Gambia border,
the prevalence of malaria decreased from 87.2 to 0.3% in
children and 58.3 to 0.3% from 1990 to 2012 [12].
The prevalence of isolates with reduced susceptibility to
MQ remained high (55.6%) in Dakar, but was relatively
stable compared with the previous year (55 to 62%) [3,10].
The level of in vitro MQ resistance increased since previ-
ous studies conducted in Dakar. In Dakar, the per cent of
isolates with decreased susceptibility was 17% in 2001 [13]
and 13% in 2002 [7]. MQ prophylaxis failure has been pre-
viously described in Senegal [14], and MQ is one of the
three anti-malarial drugs recommended for travellers as
an anti-malarial prophylaxis in Senegal. Clinical trials are
in progress to evaluate the efficacy of MQ for intermittent
preventive treatment of infants and pregnant women,
whereas MQ is still used for the treatment of uncompli-
cated malaria in infants in Dakar. Nevertheless, MQ has
been employed relatively infrequently in Africa compared
to Asia. The combination of artesunate-mefloquine, which
is administered to patients in Asia, is not yet used in
Senegal. However, scientific data are not available for MQ
monotherapy, and very little data are available on the
in vitro decreased susceptibility to MQ and its clinical im-
plications in Africa. It is important to monitor the evolu-
tion of P. falciparum susceptibility to MQ, to archive
suspicious isolates and to correlate clinical outcomes with
pharmacokinetic and phenotypic responses and with mo-
lecular markers.
As far back as 1988, in vitro P. falciparum resistance
to CQ was reported in Dakar, and reports of resistanceisolates from Dakar to chloroquine (CQ),
ihydroartemisinin (DHA), quinine (QN), mefloquine
Q) and Proveblue (PVB)
Resistance or reduced susceptibility
Max Cut-off %
346.4 77 nM 50.0
117.1 61 nM 5.6
82.9 115 nM 0
5.08 12 nM 0
5.53 12 nM 0
1430 611 nM 5.6
63.4 30 nM 55.6
19.7 ND ND
168.0 ND ND
40.2 ND ND
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after [15]. From 1991 to 1995, parasitological failures
were observed in 21% of patients in Pikine [16]. The
prevalence of in vitro CQ resistance then decreased in
from 52% in 2002 [7] to approximately 20-25% in Dakar
in 2009–2011 [3,10]. In 2013–2014, the prevalence of
in vitro resistance to CQ in Dakar increased again to
50%. A limitation of these results is the very small num-
ber of studied samples. However, this phenomenon was
already described in Thies and Pikine. Parasites also
became less susceptible to CQ from 2008 (median IC50
= 30.7 nM) to 2011 (median IC50 = 76.1 nM) in Thies
[4]. In Pikine, after a decrease of the prevalence of the
pfcrt 76 T mutation, involved in CQ resistance, from
64-79% before CQ withdrawal (2000 to 2003) [17-19] to
47-60% [20,21] when amodiaquine plus pyrimethamine-
sulphadoxine was the first-line treatment (2004–2005),
this prevalence has increased slightly to 59% since ACT
has been implemented (2006 to 2009) [19]. It is import-
ant to monitor the evolution of P. falciparum suscepti-
bility to CQ.
The decrease in CQ resistance parallels the withdrawal
of CQ treatment and the introduction of ACT in 2002
in Senegal. However, in 2006, CQ was still being admin-
istered to patients. In Dakar in 2006, CQ represented
5.1% of the anti-malarial drugs used in children [22] and
3.5% in 2009 [23]. The rapid dissemination of CQ resist-
ance in Dielmo, despite strictly controlled anti-malarial
drug use, argues against the re-introduction of CQ, at
least in monotherapy, in places where the resistance al-
lele has dropped to very low levels following the discon-
tinuation of CQ treatment [24]. Despite the re-aquisition
of CQ susceptibility, any re-introduction would likely
result in a rapid re-emergence of resistant strains.
Additionally, the increase of CQ resistance in the hypo-
thetical absence of CQ pressure leads to an avoidance of
re-introducing CQ in Senegal. There is an urgent need
to evaluate the presence and use of CQ in Dakar and to
evaluate the capacity of drug pressure on CQ resistance
of the different partners combined with artemisinin
derivatives in ACT.
The prevalence of isolates with in vitro-reduced
susceptibility to MDAQ remains low and stable in 2013
(5.6 versus 6% in 2009 and 11.8% in 2010) [3,10]. The
resistance to amodiaquine has remained low even after
the introduction of artesunate-amodiaquine in 2006 in
Senegal. A study in Dakar and Mlomp from 1996 to
1998 demonstrated that monotherapy with amodiaquine
remained effective for treating uncomplicated malaria in
areas where CQ resistance was prevalent [25]. In 2011–
2012, the efficacy of ASAQ was evaluated at 99.3% [26].
However, ACT efficacy and resistance must be moni-
tored because clinical failures, or at least extended para-
site clearance times, have been described in SoutheastAsia [27-30]. In this context, it is important to imple-
ment in vitro and in vivo surveillance programmes.
No isolate exhibited reduced in vitro susceptibility to
DHA or to AS. This result is consistent with previous
studies that did not show any parasites resistant to AS
[7,31,32]. However, high IC50 values can be found for ar-
temisinin, with an IC50 > 30 nM in Dakar [33] and AS
with an IC50 > 45 nM [13]. The median IC50 values in-
creased from 2008 to 2011 (3.2 to 10.1 nM) with a high-
est IC50 value of 73.1 nM in Thies [4]. In the present
study, IC50 ranged from 0.1 to 5.08 nM for DHA and
0.12 to 8.53 nM for AS. However, the standard in vitro
test was not adapted to follow resistance to artemisinin
derivatives. The clinical resistance to artemisinin corre-
lated with in vitro resistance, manifested by an increase
in the ring-stage survival rate after contact with artemi-
sinin (ring survival test) [34,35]. In addition, mutations
in the P. falciparum K13 gene (PF3D7_1343700) that
encodes the kelch propeller domain were associated with
in vitro resistance to artemisinin and with delayed
clearance after artemisinin treatment in southern Asia
[30,36,37]. It will be a priority to introduce this new
in vitro test in Senegal.
The other ACT first-line treatment for uncomplicated
P. falciparum malaria in Senegal is the combination of
artemether-lumefantrine. No isolate presented reduced
susceptibility to LMF, and this prevalence was remains
under 3% in Dakar since the introduction of ACT [3,10].
In 2011–2012, the efficacy of artemether-lumefantrine
was evaluated at 100% in Senegal [26].
A new ACT second-line treatment for uncomplicated
P. falciparum malaria in Senegal is the combination of
dihydroartemisinin-piperaquine (DP). DP (Artekin®,
Duo-Cotecxin®, Eurartesim®) is administered as single
daily dose for three days. It has been demonstrated to be
well tolerated and highly effective for the treatment of
uncomplicated P. falciparum malaria in Africa [38-40].
In 2011–2012, the efficacy of DP was evaluated at 100%
in Senegal [26]. The PPQ IC50 values (geometric mean
IC50 = 32.2 nM) observed in Dakar in 2013 were slightly
lower than those found in other ex vivo studies in Africa
(geometric mean IC50 = 81.3 nM and 66.8 nM) [41,42].
The pyronaridine-artesunate combination (Pyramax®)
is one of the most recent ACT combinations and is cur-
rently under development by the not-for-profit organisa-
tion Medicines for Malaria Venture (Geneva, Switzerland)
and the pharmaceutical company Shin Poong Pharmaceu-
ticals (Seoul, Republic of Korea) for the treatment of
uncomplicated P. falciparum malaria and for the
blood stages of Plasmodium vivax malaria. The effi-
cacy of PND-artesunate was not inferior to that of
artemether-lumefantrine in the treatment of uncompli-
cated P. falciparum malaria in Africa [43]. The PND IC50
values (geometric mean IC50 = 5.8 nM) observed in Dakar
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1996 and 1997 (3.8 nM and 4.52 nM) [44,45].
In 2013, 7% of isolates showed low reduced suscepti-
bility to QN, which is in accordance with previous stud-
ies in Dakar [3,7,10,13]. Even in areas where QN efficacy
remains good, such as sub-Saharan Africa, the suscepti-
bility of individual P. falciparum isolates to QN has var-
ied widely. The IC50s for isolates collected in Dakar were
6 to 1,291 nM in 2009 [10] and 5 to 1,195 nM in 2010
[3]. The wide range in QN susceptibility and recent evi-
dence for QN treatment failure observed across Africa
[46,47] or in Senegal in a patient who spent two months
in Dielmo in 2007 [48] suggest that the evolution of par-
asites with reduced susceptibility may contribute to QN
decreased efficacy. However, the 24 patients in this study
were successfully treated with QN.
Proveblue (PVB), which is a methylene blue prepar-
ation that complies with the European Pharmacopoeia
and contains limited organic impurities and heavy
metals of recognized toxicity, has previously been dem-
onstrated to possess in vitro anti-malarial activity against
23 P. falciparum strains that were resistant to various
anti-malarial drugs [49]. PVB exhibited noticeable syner-
gistic effects in combination with MQ and QN and high
synergistic effects associated with DHA [50]. Treatment
with 1 to 10 mg/kg of weight of PVB for five days sig-
nificantly reduced or prevented cerebral malaria in mice
[51-53]. The IC50 for PVB ranged from 0.88 nM to 40.2
nM with a mean of 5.3 nM. These data show that PVB
is active in vitro, in line with previous studies with
methylene blue with organic as well as inorganic impur-
ities in parasites from Nigeria, Kenya and Thailande
[54-56]. Another advantage of the use of PVB is that
methylene blue has gametocytocidal properties and can
reduce the transmission of P. falciparum [57,58].
Limitations must be taken into account such as the
very small number of samples which are not represen-
tative of susceptibility in Senegal but only from a facil-
ity in Dakar, the Hôpital Principal de Dakar, which
certainly selects most severe malaria than in neighborhood
clinics.
The introduction of ACT in 2002 in Senegal did not
induce a decrease in P. falciparum susceptibility to indi-
vidual drug components, such as DHA, AS, MDAQ, and
LMF. The prevalence of P. falciparum isolates with re-
duced drug susceptibility to MQ remains high and stable
in Dakar. Since 2004, the prevalence of CQ resistance
has decreased, but then rebounded in 2013 in Dakar.
PND, PPQ and PVB showed high in vitro activity against
P. falciparum parasites from Dakar. Maximizing the effi-
cacy and longevity of ACT as a tool to control malaria
will critically depend on pursuing intensive research into
identifying in vitro markers as well as implementing
ex vivo and in vivo surveillance programmes.Competing interests
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